← Back to Search

Curcumin Therapy for COPD

N/A

Waitlist Available

Led By Oleg Sostin, MD

Research Sponsored by Danbury Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will compare the effects of curcumin (a natural substance found in the spice turmeric) vs. a placebo on 120 patients with COPD.

Who is the study for?

This trial is for individuals with COPD who have smoked at least 10 pack-years, have specific lung function test results, and haven't had a flare-up in the last month. They must not use turmeric recently or be on certain medications, pregnant, lactating, or unable to do a walking test due to non-COPD issues.Check my eligibility

What is being tested?

The study tests if curcumin therapy improves COPD management over 90 days compared to placebo. All participants will continue their usual care. The effects of curcumin are measured against those receiving an inactive substance in this double-blind setup where neither doctors nor patients know who's getting what.See study design

What are the potential side effects?

Curcumin is generally considered safe but may cause digestive upset like nausea or diarrhea in some people. Since it's being tested alongside standard treatments for COPD, other side effects could include typical reactions to those existing medications.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

St. George's Respiratory Questionnaire (SGRQ-C) score

Secondary outcome measures

Performance on the 6-minute walk test (6MWT)

Relative risk of hospital admission for acute COPD exacerbation.

Chronic Obstructive Airway Disease

+1 more

Trial Design

2Treatment groups

Active Control

Group I: Active Comparator: Placebo with Standard COPD careActive Control2 Interventions

Subjects will be given instructions to take 1 capsule twice daily for 90 days, 30 min before or 1 hour after meals, with a glass of water; if they develop upset stomach or diarrhea, then to take the medication with meals. This treatment will be in addition to the usual care that the hospital physician prescribe for them to treat the COPD.

Group II: Active Comparator: Curcumin therapy added to standard COPD careActive Control2 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Danbury HospitalLead Sponsor

10 Previous Clinical Trials

1,239 Total Patients Enrolled

Oleg Sostin, MDPrincipal InvestigatorDanbury Hospital, Nuvance Health

Media Library

Active Comparator: Curcumin therapy added to standard COPD care Clinical Trial Eligibility Overview. Trial Name: NCT04687449 — N/A

Chronic Obstructive Pulmonary Disease Research Study Groups: Active Comparator: Placebo with Standard COPD care, Active Comparator: Curcumin therapy added to standard COPD care

Chronic Obstructive Pulmonary Disease Clinical Trial 2023: Active Comparator: Curcumin therapy added to standard COPD care Highlights & Side Effects. Trial Name: NCT04687449 — N/A

Active Comparator: Curcumin therapy added to standard COPD care 2023 Treatment Timeline for Medical Study. Trial Name: NCT04687449 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial actively enrolling participants?

"As per the clinicaltrials.gov website, this research program is not presently accepting participants; it was first posted on January 1st 2022 and edited most recently on July 8th 2021. Nevertheless, there are 337 other medical studies recruiting patients at present."

Answered by AI

Are elderly patients being included in this clinical trial?

"The requirements for this trial dictate that applicants should be between 40 and 89 years of age. There are 14 studies available to those younger than 18, while 333 can be found for individuals over the senior cutoff."

Answered by AI

What are the qualifications necessary to participate in this investigation?

"This medical study is currently enrolling 120 volunteers aged between 40 and 89 who suffer from chronic obstructive airway disease. Furthermore, to qualify for the trial, patients must have a smoking history of at least 10 pack-years, their FEV1/FVC ratio must be less than 70%, their post bronchodilator FEV1 should be lower than 80% of its predicted value, not had an acute exacerbation in the past 4 weeks and agree to comply with all procedures throughout the duration of the experiment."

Answered by AI